Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Borentain

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Chest|July 12, 2016
ResponsePatrick Borentain, Sébastien Renard, Philippe Colson
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 12, 2019
Hepatitis E virus as an agent of hepatocellular carcinomaPhilippe Colson, Patrick Borentain, René Gérolami
The Journal of Infectious Diseases|October 20, 2019
Hepatitis B Virus Genomics Knocking at the Door of Routine Diagnostic LaboratoriesPhilippe Colson, Patrick Borentain, Isabelle Ravaux, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 29, 2017
A foretold hepatitis A outbreak in FranceAurélie Martin, Amélie Menard, Patrick Borentain, et al.
Clinics and Research in Hepatology and Gastroenterology|October 23, 2022
Bulevirtide 2mg-based real-life treatment of hepatitis Delta with genotypes 1 and 5 viruses at more than 20 months of follow-upClara Dassetto, Patrick Borentain, René Gérolami, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 27, 2015
Optimal duration of pre-liver transplantation anti-hepatitis C virus treatment with direct-acting agent sofosbuvirPatrick Borentain, Philippe Colson, Albert Darque, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 29, 2016
Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapyPatrick Borentain, Emilie Gregoire, Guillaume Louis, et al.
International Journal of Antimicrobial Agents|May 18, 2016
Fulminant hepatitis B virus reactivation following antiviral treatment interruption in a chronically infected patientPatrick Borentain, Fatih Dinc, René Gerolami, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 15, 2011
Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitorsPhilippe Colson, Raj Purgus, Patrick Borentain, et al.
Journal of Travel Medicine|December 11, 2023
Liver transplantation due to fulminant hepatitis A in a traveller visiting friends and relatives in ComorosSafiétou Diallo, Patrick Borentain, Anne Motte, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Chest|July 12, 2016
ResponsePatrick Borentain, Sébastien Renard, Philippe Colson
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 12, 2019
Hepatitis E virus as an agent of hepatocellular carcinomaPhilippe Colson, Patrick Borentain, René Gérolami
The Journal of Infectious Diseases|October 20, 2019
Hepatitis B Virus Genomics Knocking at the Door of Routine Diagnostic LaboratoriesPhilippe Colson, Patrick Borentain, Isabelle Ravaux, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 29, 2017
A foretold hepatitis A outbreak in FranceAurélie Martin, Amélie Menard, Patrick Borentain, et al.
Clinics and Research in Hepatology and Gastroenterology|October 23, 2022
Bulevirtide 2mg-based real-life treatment of hepatitis Delta with genotypes 1 and 5 viruses at more than 20 months of follow-upClara Dassetto, Patrick Borentain, René Gérolami, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 27, 2015
Optimal duration of pre-liver transplantation anti-hepatitis C virus treatment with direct-acting agent sofosbuvirPatrick Borentain, Philippe Colson, Albert Darque, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 29, 2016
Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapyPatrick Borentain, Emilie Gregoire, Guillaume Louis, et al.
International Journal of Antimicrobial Agents|May 18, 2016
Fulminant hepatitis B virus reactivation following antiviral treatment interruption in a chronically infected patientPatrick Borentain, Fatih Dinc, René Gerolami, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 15, 2011
Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitorsPhilippe Colson, Raj Purgus, Patrick Borentain, et al.
Journal of Travel Medicine|December 11, 2023
Liver transplantation due to fulminant hepatitis A in a traveller visiting friends and relatives in ComorosSafiétou Diallo, Patrick Borentain, Anne Motte, et al.
Pageof 7